Addendum. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020. Diabetes Care 2020;43(Suppl. 1):S98

Addendum. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020. Diabetes Care 2020;43(Suppl. 1):S98–S110

Published:2020-06-05 Issue:8 Volume:43 Page:1979-1979
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:Dia Care

Author:

Publisher

American Diabetes Association

Subject

Advanced and Specialised Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference1 articles.

1. U.S. Food and Drug Administration . FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. 19 March 2020 update [FDA Drug Safety Communication]. Available from https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oral Anti-Diabetic Semaglutide: A GLP-1 RA Peptide;International Journal of Innovative Science and Research Technology (IJISRT);2024-07-10

2. Sociodemographic disparities in GLP-1RA and SGLT2i use among US adults with type 2 diabetes: NHANES 2005-March 2020;Current Medical Research and Opinion;2024-01-16

3. Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial;Beni-Suef University Journal of Basic and Applied Sciences;2023-11-08

4. Role of Oxidative Stress in Tuberculosis Meningitis Infection in Diabetics;Biomedicines;2023-09-19

5. Sociodemographic disparities in the use of GLP-1 receptor agonists and SGLT-2 inhibitors among US adults with type 2 diabetes: NHANES 2005-March 2020;2023-03-31